TX-SOFTSERVE
2.12.2021 13:07:03 CET | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has released its second bi-annual Sustainability Report . The report, prepared according to GRI Standards, highlights progress made against the company’s ongoing commitment to a sustainable business strategy, featuring key initiatives and achievements that positively impact society and the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005018/en/
“As a global organization, we must take responsibility towards our associates, customers, and communities,” said Chris Baker, CEO at SoftServe. “SoftServe is a people-centric company, focused on creating an inclusive workplace that supports our associates’ well-being, access to education, and innovation, which enables us to support sustainable development in our communities around the world.”
“In 2020 the world faced extraordinary new challenges that impacted each of us as individuals, and as a business,” said Taras Vervega, co-founder and board member at SoftServe. “It was another moment that revealed who we are as a company. The way SoftServe responded to the pandemic, the numerous solutions we have created to help our clients, and the massive response of our company and our people to help hospitals and local communities – all make me very proud of the company we’ve built.”
Diversity, Equality, and Inclusion
Since 2018, SoftServe has made significant progress towards gender equality, as the rate of women in managerial roles grew from 35% in 2018 to 49% in 2020. Additionally, as part of its inclusivity efforts, in 2020 the company launched its first learning course in accessibility testing for visually impaired people , and its graduates are now part of SoftServe’s accessibility testing team.
Advancing IT Education
Developing IT education is another focus of the company’s social initiatives. SoftServe’s IT Academy , an educational platform for students and graduates, enrolled 2,759 students and subsequently hired 1,368 graduates upon completion of its programs over the last two years. SoftServe currently maintains partnerships with 34 universities and tech schools in Ukraine, Bulgaria, and Poland, establishing new IT bachelor’s degree programs, launching tech labs, and hosting numerous educational events.
Empowering Communities
SoftServe’s approach to social responsibility includes empowering its people to give back to their communities. In 2020 SoftServe became strategic partner to UNICEF Ukraine. The parties cooperated on educational programs and initiatives in Ukraine to exchange knowledge and professional experience and worked together on several pro bono technology solutions.
Throughout 2020, SoftServe built a framework to engage associates in pro bono projects that address pressing social issues and created the company’s Open Tech crowdsourcing platform. Together with NGOs and governmental institutions, SoftServe contributed to a number of projects, including Ukraine’s National Volunteer Platform , created with UNICEF Ukraine, the Ukrainian Volunteer Service, and the Ministry of Youth and Sports of Ukraine. The Platform is an online portal that helps connect volunteers with opportunities around social assistance, education and science, culture, art, and more.
SoftServe also developed a COVID-19 triage chatbot for the Bulgarian government to provide citizens with critical information, answers to frequently asked questions, and healthcare contact information to help assess symptoms and navigate the next steps. Using advanced conversational AI, the triage chatbot quickly assesses users with a series of text or voice questions, eliminating staff burden and soothing patient fears. It is an omnichannel communication tool available on any smartphone, computer, or tablet, and can help to triage patients in under 30 seconds.
Other key social achievements include:
- 4 international awards for SoftServe’s corporate social responsibility and sustainability initiatives and projects
- 92 volunteer and charitable projects accomplished in 2019–2020
- 50+ events launched dedicated to emotional health and employee well-being
- 752 computers donated to educational establishments in 2019-2020
- 10,000+ trees planted in 2019–2020
- $882,500 contributed to projects implemented by SoftServe’s “Open Eyes” charity fund in 2019–2020
- 10+ tons of medical equipment funded via SoftServe & “Open Eyes” charity fund
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation - from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005018/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
